nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—BCHE—Synthesis of PC—CHKB—narcolepsy	0.104	0.129	CbGpPWpGaD
Mivacurium—BCHE—Glycerophospholipid biosynthesis—CHKB—narcolepsy	0.0306	0.0378	CbGpPWpGaD
Mivacurium—CHRNA2—forebrain—narcolepsy	0.0286	0.151	CbGeAlD
Mivacurium—BCHE—Phospholipid metabolism—CHKB—narcolepsy	0.0213	0.0263	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—HRH3—narcolepsy	0.0208	0.0257	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—HRH3—narcolepsy	0.0206	0.0254	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—P2RY11—narcolepsy	0.0195	0.024	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—P2RY11—narcolepsy	0.0193	0.0238	CbGpPWpGaD
Mivacurium—CHRNB1—medulla oblongata—narcolepsy	0.0192	0.101	CbGeAlD
Mivacurium—CHRNB1—midbrain—narcolepsy	0.0176	0.0925	CbGeAlD
Mivacurium—CHRM2—forebrain—narcolepsy	0.0171	0.0898	CbGeAlD
Mivacurium—CHRNA1—brain—narcolepsy	0.0143	0.0753	CbGeAlD
Mivacurium—CHRM3—forebrain—narcolepsy	0.0139	0.0732	CbGeAlD
Mivacurium—CHRM3—Monoamine GPCRs—HTR2A—narcolepsy	0.0123	0.0152	CbGpPWpGaD
Mivacurium—CHRM2—Monoamine GPCRs—HTR2A—narcolepsy	0.0122	0.0151	CbGpPWpGaD
Mivacurium—CHRNA2—brain—narcolepsy	0.0119	0.0625	CbGeAlD
Mivacurium—BCHE—brainstem—narcolepsy	0.0118	0.0619	CbGeAlD
Mivacurium—BCHE—forebrain—narcolepsy	0.0113	0.0597	CbGeAlD
Mivacurium—CHRM3—G alpha (q) signalling events—HCRTR2—narcolepsy	0.0113	0.014	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—HCRTR1—narcolepsy	0.0113	0.014	CbGpPWpGaD
Mivacurium—CHRNB1—brain—narcolepsy	0.0111	0.0581	CbGeAlD
Mivacurium—CHRM3—G alpha (q) signalling events—P2RY11—narcolepsy	0.0109	0.0135	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—HTR2A—narcolepsy	0.0104	0.0128	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—HTR2A—narcolepsy	0.0103	0.0127	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR2—narcolepsy	0.0101	0.0125	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR1—narcolepsy	0.0101	0.0125	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—P2RY11—narcolepsy	0.00978	0.0121	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—HCRT—narcolepsy	0.0093	0.0115	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.00876	0.0108	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.00876	0.0108	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.00867	0.0107	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.00867	0.0107	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.00846	0.0104	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.00837	0.0103	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HCRT—narcolepsy	0.00832	0.0103	CbGpPWpGaD
Mivacurium—BCHE—medulla oblongata—narcolepsy	0.0082	0.0431	CbGeAlD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.0075	0.00926	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.0075	0.00926	CbGpPWpGaD
Mivacurium—BCHE—midbrain—narcolepsy	0.00749	0.0394	CbGeAlD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.00743	0.00917	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.00743	0.00917	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.00725	0.00895	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.00718	0.00886	CbGpPWpGaD
Mivacurium—CHRM2—brain—narcolepsy	0.00708	0.0373	CbGeAlD
Mivacurium—CHRM3—G alpha (q) signalling events—TRH—narcolepsy	0.00705	0.0087	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	0.00687	0.00848	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—PENK—narcolepsy	0.00684	0.00844	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—narcolepsy	0.00631	0.00778	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.00616	0.00761	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.0061	0.00753	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.00586	0.00724	CbGpPWpGaD
Mivacurium—CHRM3—brain—narcolepsy	0.00577	0.0304	CbGeAlD
Mivacurium—CHRM3—GPCR ligand binding—HCRTR2—narcolepsy	0.00571	0.00705	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HCRTR1—narcolepsy	0.00571	0.00705	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HCRTR1—narcolepsy	0.00566	0.00699	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HCRTR2—narcolepsy	0.00566	0.00699	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—P2RY11—narcolepsy	0.00552	0.00681	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.00549	0.00678	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—HTR2A—narcolepsy	0.00548	0.00677	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—P2RY11—narcolepsy	0.00546	0.00675	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.00544	0.00671	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—HTR2A—narcolepsy	0.00543	0.0067	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—NPS—narcolepsy	0.00512	0.00632	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—TAC1—narcolepsy	0.00512	0.00632	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—HRH3—narcolepsy	0.0051	0.0063	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.00478	0.0059	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.00473	0.00584	CbGpPWpGaD
Mivacurium—BCHE—brain—narcolepsy	0.00471	0.0248	CbGeAlD
Mivacurium—CHRM3—GPCR ligand binding—HCRT—narcolepsy	0.00469	0.00579	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	0.00467	0.00577	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.00467	0.00576	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HCRT—narcolepsy	0.00465	0.00574	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.00462	0.00571	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—narcolepsy	0.00458	0.00566	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—narcolepsy	0.00458	0.00566	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—PENK—narcolepsy	0.00418	0.00516	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—PENK—narcolepsy	0.00414	0.00511	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.00409	0.00505	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.00405	0.00501	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—TRH—narcolepsy	0.00356	0.00439	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—HTR2A—narcolepsy	0.00353	0.00436	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—TRH—narcolepsy	0.00352	0.00435	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.00339	0.00419	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.00339	0.00419	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.00336	0.00415	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.00336	0.00415	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HCRTR1—narcolepsy	0.00323	0.00399	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HCRTR2—narcolepsy	0.00323	0.00399	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HCRTR2—narcolepsy	0.0032	0.00395	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HCRTR1—narcolepsy	0.0032	0.00395	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—P2RY11—narcolepsy	0.00312	0.00385	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HRH3—narcolepsy	0.00312	0.00385	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—P2RY11—narcolepsy	0.00309	0.00381	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HRH3—narcolepsy	0.00309	0.00381	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—HTR2A—narcolepsy	0.00308	0.0038	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CHKB—narcolepsy	0.00306	0.00378	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HCRTR2—narcolepsy	0.00293	0.00362	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HCRTR1—narcolepsy	0.00293	0.00362	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HCRTR2—narcolepsy	0.0029	0.00358	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HCRTR1—narcolepsy	0.0029	0.00358	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—P2RY11—narcolepsy	0.00283	0.0035	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—P2RY11—narcolepsy	0.0028	0.00346	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—narcolepsy	0.00276	0.0034	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HCRT—narcolepsy	0.00265	0.00327	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HCRT—narcolepsy	0.00263	0.00324	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—TAC1—narcolepsy	0.00258	0.00319	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—NPS—narcolepsy	0.00258	0.00319	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—NPS—narcolepsy	0.00256	0.00316	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—TAC1—narcolepsy	0.00256	0.00316	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HCRT—narcolepsy	0.00241	0.00297	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HCRT—narcolepsy	0.00238	0.00294	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.00238	0.00294	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PENK—narcolepsy	0.00236	0.00292	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.00236	0.00291	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CHKB—narcolepsy	0.00235	0.0029	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PENK—narcolepsy	0.00234	0.00289	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PENK—narcolepsy	0.00215	0.00265	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PENK—narcolepsy	0.00213	0.00262	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CPT1B—narcolepsy	0.00208	0.00257	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.00204	0.00252	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.00202	0.0025	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—TRH—narcolepsy	0.00201	0.00248	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—TRH—narcolepsy	0.00199	0.00246	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—TRH—narcolepsy	0.00182	0.00225	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—TRH—narcolepsy	0.00181	0.00223	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HRH3—narcolepsy	0.00176	0.00218	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HRH3—narcolepsy	0.00174	0.00215	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HCRTR2—narcolepsy	0.00173	0.00214	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HCRTR1—narcolepsy	0.00173	0.00214	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HCRTR1—narcolepsy	0.00172	0.00212	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HCRTR2—narcolepsy	0.00172	0.00212	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—P2RY11—narcolepsy	0.00167	0.00207	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—P2RY11—narcolepsy	0.00166	0.00205	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HRH3—narcolepsy	0.0016	0.00198	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CPT1B—narcolepsy	0.0016	0.00197	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HRH3—narcolepsy	0.00158	0.00196	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HTR2A—narcolepsy	0.00155	0.00192	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HTR2A—narcolepsy	0.00154	0.0019	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—TNF—narcolepsy	0.00152	0.00187	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—NPS—narcolepsy	0.00146	0.0018	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—TAC1—narcolepsy	0.00146	0.0018	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—NPS—narcolepsy	0.00145	0.00178	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—TAC1—narcolepsy	0.00145	0.00178	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HCRT—narcolepsy	0.00142	0.00176	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HCRT—narcolepsy	0.00141	0.00174	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—NPS—narcolepsy	0.00133	0.00164	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—TAC1—narcolepsy	0.00133	0.00164	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—TAC1—narcolepsy	0.00131	0.00162	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—NPS—narcolepsy	0.00131	0.00162	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PENK—narcolepsy	0.00127	0.00157	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PENK—narcolepsy	0.00126	0.00155	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TRH—narcolepsy	0.00108	0.00133	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TRH—narcolepsy	0.00107	0.00132	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HRH3—narcolepsy	0.000945	0.00117	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HRH3—narcolepsy	0.000936	0.00116	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HTR2A—narcolepsy	0.000878	0.00108	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HTR2A—narcolepsy	0.00087	0.00107	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HTR2A—narcolepsy	0.000798	0.000985	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HTR2A—narcolepsy	0.00079	0.000975	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TAC1—narcolepsy	0.000783	0.000967	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NPS—narcolepsy	0.000783	0.000967	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TAC1—narcolepsy	0.000776	0.000958	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NPS—narcolepsy	0.000776	0.000958	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR2A—narcolepsy	0.000471	0.000582	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR2A—narcolepsy	0.000467	0.000576	CbGpPWpGaD
